ConductScience.org, home

Paper40960554

The benefits of combining an immunomodulator with a chemotherapy agent in chondrosarcoma-a proof of concept with mifamurtide.

Quoniou R and 5 others. Med Oncol, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. The benefits of combining an immunomodulator with a chemotherapy agent in chondrosarcoma-a proof of concept with mifamurtide. Papers, record 40960554. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40960554

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The benefits of combining an immunomodulator with a chemotherapy agent in chondrosarcoma-a proof of concept with mifamurtide.
PubMed
Journal
Med Oncol
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-11-05
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Quoniou RRohan
2Bortoli EElisa
3Moreau EEmmanuel
4Cachin FFlorent
5Chautard EEmmanuel
6Peyrode CCaroline

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ChondrosarcomaMajor topic
Bone NeoplasmsMajor topic
Acetylmuramyl-Alanyl-IsoglutamineMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Humans
Animals
Mice
Tumor-Associated Macrophages
Cell Line, Tumor
Proof of Concept Study
Doxorubicin
Xenograft Model Antitumor Assays
Coculture Techniques
Phosphatidylethanolamines

Source PubMed

Download CSV of topics

References50

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137958467The Role of Macrophages in Sarcoma Tumor Microenvironment and Treatment.Cancers (Basel)2023https://conductscience.org/library/papers/37958467PubMed
237174021Molecular In-Depth Characterization of Chondrosarcoma for Current and Future Targeted Therapies.Cancers (Basel)2023https://conductscience.org/library/papers/37174021PubMed
323483678Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.Oncoimmunology2013https://conductscience.org/library/papers/23483678PubMed
436868333Lactate induces tumor-associated macrophage polarization independent of mitochondrial pyruvate carrier-mediated metabolism.Int J Biol Macromol2023https://conductscience.org/library/papers/36868333PubMed
533912442High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease.Front Oncol2021https://conductscience.org/library/papers/33912442PubMed
626912558Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies.Ann Oncol2016https://conductscience.org/library/papers/26912558PubMed
712115575Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro.Int J Cancer2002https://conductscience.org/library/papers/12115575PubMed
823348699Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer.Cancer Lett2013https://conductscience.org/library/papers/23348699PubMed
927312065Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype.Mod Pathol2016https://conductscience.org/library/papers/27312065PubMed
1031412220CD40 Agonist Antibodies in Cancer Immunotherapy.Annu Rev Med2020https://conductscience.org/library/papers/31412220PubMed
1110884587Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393, in combination with cyclophosphamide.Int J Immunopharmacol2000https://conductscience.org/library/papers/10884587PubMed
1226966341Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment.Mediators Inflamm2016https://conductscience.org/library/papers/26966341PubMed
1328380460CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.Oncotarget2017https://conductscience.org/library/papers/28380460PubMed
1431629410Tumor-associated macrophages: an accomplice in solid tumor progression.J Biomed Sci2019https://conductscience.org/library/papers/31629410PubMed
1529632713CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT.Oncoimmunology2018https://conductscience.org/library/papers/29632713PubMed
16348300823D Cell Culture Systems: Tumor Application, Advantages, and Disadvantages.Int J Mol Sci2021https://conductscience.org/library/papers/34830082PubMed
1727994517Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway.Int J Biol Sci2016https://conductscience.org/library/papers/27994517PubMed
1828704566Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing.PLoS One2017https://conductscience.org/library/papers/28704566PubMed
1922314082Contribution of CXCL12 secretion to invasion of breast cancer cells.Breast Cancer Res2012https://conductscience.org/library/papers/22314082PubMed
2025082815CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.Cancer Res2014https://conductscience.org/library/papers/25082815PubMed

See all 50 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40960554

GET https://conductscience.org/api/papers/v1/40960554/references?page=2